P., Zhu, Z
Who responds best to CagriSema Ideal candidates: Significant obesity (BMI 30-40+) Previously plateaued on GLP-1s alone Need maximum weight loss Good GI tolerability Metabolic syndrome or diabetes Commitment to long-term use Excellent responders: Higher baseline weight (more to lose) Good adherence to protocol Combine with diet/exercise Younger patients (better metabolism) No significant medication interactions May respond less optimally: Very low starting weight (BMI 30%): Nausea (most common) Decreased appetite (intended effect) Constipation Fatigue (especially first months) Common (10-30%): Vomiting (if nausea not managed) Diarrhea (alternating with constipation) Abdominal pain/discomfort Headache Dizziness Less common ( 40 with comorbidities Insurance covers surgery Want permanent solution Don't want ongoing injections Sourcing cagrilintide and semaglutide Obtaining these peptides requires understanding current availability
In this scenario, focusing on the ITT and LATE alone would lead a policymaker to over-estimate the potential impact of the job-training program in terms of increases in employment
The goal is to actually understand the pharmacology, the physiology, and the real-world evidence as it accumulates, and use that to build protocols that are up to date, efficient, and based in science
Always consult your healthcare provider before choosing the right option for your needs
In a recent clinical trial done through the departments of Clinical Pathophysiology and Biomedical Science and Human Oncology at the University of Turin in Italy, supplementation with vitamin B12 reduced or eliminated chronic cough in some patients
